QuantHealth, a leading company in AI-powered clinical trial simulation, has secured a strategic investment from Sanofi Ventures, the investment arm of the global pharmaceutical giant Sanofi. This funding will support QuantHealth in advancing its patient-level simulation technology and digital twin platform, helping to usher in a new era for drug development. With this latest investment, QuantHealth has now raised a total of $30 million.
Health Technology Insights: Dentsply Sirona and Pearl Team Up for AI Radiology Support
QuantHealth’s platform enables pharmaceutical companies to virtually run clinical trials by generating millions of digital patient replicas based on real-world data and advanced AI algorithms. This method helps predict trial outcomes, refine study designs, and boost success rates while cutting down on time and costs.
The investment also strengthens the partnership between QuantHealth and Sanofi, supporting Sanofi’s goal of integrating AI and digital solutions throughout its research and development processes. As part of the agreement, Cris De Luca, a Partner at Sanofi Ventures, will join QuantHealth’s Board of Directors as an observer.
Health Technology Insights: Healthmine Appoints Dwight Erskine as New Chief Executive Officer
Orr Inbar, CEO and Co-founder of QuantHealth, expressed excitement about the collaboration, stating that Sanofi’s leadership in digital transformation will help support QuantHealth’s mission to expand AI-driven clinical trial innovation. He highlighted that this partnership will speed up the adoption of predictive technologies in drug development.
Cris De Luca from Sanofi Ventures praised QuantHealth’s unique use of digital twins and real-world data as a major advancement in pharmaceutical R&D. He expressed enthusiasm about working closely with the company and contributing to its growth. Emmanuel Frenehard, Chief Digital Officer at Sanofi, emphasized the company’s commitment to becoming an AI-first organization. He pointed out that working with innovators like QuantHealth offers a great opportunity to reimagine clinical trial design and enhance drug development through simulation. This investment and partnership reflect a shared commitment to responsibly using artificial intelligence to transform the life sciences industry and speed up the development of new treatments for patients around the world.
Health Technology Insights: Gwynedd Mercy University Opens Frances Maguire Healthcare Center
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
